Aimmune Therapeutics, Inc. 4
4 · Aimmune Therapeutics, Inc. · Filed Feb 24, 2017
Insider Transaction Report
Form 4
Knapp Jeffrey H
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2017-02-24+90,000→ 90,000 totalExercise: $19.63Exp: 2027-02-24→ Common Stock (90,000 underlying)
Holdings
- 2,776
Common Stock, $0.0001 par value
Footnotes (1)
- [F1]The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.